Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EBITDA (2016 - 2025)

Seres Therapeutics' EBITDA history spans 11 years, with the latest figure at -$22.5 million for Q3 2025.

  • For Q3 2025, EBITDA fell 125.32% year-over-year to -$22.5 million; the TTM value through Sep 2025 reached -$90.2 million, down 254.19%, while the annual FY2024 figure was $136000.0, 100.12% up from the prior year.
  • EBITDA for Q3 2025 was -$22.5 million at Seres Therapeutics, up from -$24.9 million in the prior quarter.
  • Across five years, EBITDA topped out at $88.8 million in Q3 2024 and bottomed at -$71.2 million in Q1 2023.
  • The 5-year median for EBITDA is -$40.1 million (2024), against an average of -$26.5 million.
  • The largest annual shift saw EBITDA skyrocketed 325.29% in 2021 before it plummeted 187.76% in 2022.
  • A 5-year view of EBITDA shows it stood at -$50.1 million in 2021, then tumbled by 37.18% to -$68.7 million in 2022, then surged by 39.95% to -$41.2 million in 2023, then soared by 62.09% to -$15.6 million in 2024, then tumbled by 43.74% to -$22.5 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EBITDA are -$22.5 million (Q3 2025), -$24.9 million (Q2 2025), and -$27.2 million (Q1 2025).